Mortality and pre-hospitalization use of low-dose aspirin in COVID-19 patients with coronary artery disease.

Abstract

To determine whether pre‐hospitalization use of aspirin is associated with all‐cause mortality in coronavirus disease 2019 (COVID‐19) patients with coronary artery disease (CAD). We recruited 183 adult patients with CAD diagnosed with COVID‐19, including 52 taking low‐dose aspirin (mean [SD] age, 69.7 [1.1] years; 59.6% men) and 131 without using aspirin (mean [SD] age, 71.8 [0.9] years; 51.9% men), who were admitted in the Tongji hospital in Wuhan, China from January 10, 2020 to March 30, 2020. There was no difference on in‐hospital mortality between aspirin group and non‐aspirin group (21.2% vs. 22.1%, P = .885). Similarly, for critically severe COVID‐19 patients, the mortality in aspirin group was close to that in non‐aspirin group (44% vs. 45.9%, P = .872). Moreover, the percentage of patients with CAD taking low‐dose aspirin did not differ between those survivors and non‐survivors (28.7% vs. 27.5%, P = .885). Meanwhile, the usage of aspirin was not correlated with all‐cause mortality in multivariate analysis (OR = 0.944, 95% CI: 0.411‐2.172, P = .893). Collectively, our study suggested that the pre‐hospitalization use of low‐dose aspirin was not associated with the clinical outcome of patients with CAD hospitalized with COVID‐19 infections.